drugset / Trial / NCT01026428

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

NCT01026428

Phase 1/2 Completed 24 enrolled Newron Pharmaceuticals SPA
RandomizedCrossoverQuadruple-blind

Summary

The objective of this study is to investigate the effect of safinamide on levodopa blood levels, both after single and multiple dosing of safinamide . A further objective of the study is to assess the safety and tolerability of safinamide when given together with levodopa in the applied regimen. For that purpose, all study participants will undergo intensive blood sampling for investigation of levodopa levels and various tolerability examinations, such as the measurement of vital signs (blood pressure, pulse, body temperature), recording of ECGs and questioning to find out how the study participants are feeling. Furthermore, blood samples will be drawn and urine tests will be performed repeatedly for safety purpose during the course of the study. The results of this clinical trial may be used for the drug registration of safinamide in the future.

Timeline

Start
2009-09
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Levodopa Small molecule 100 mg
Subject Safinamide Small molecule 100 mg
Background Carbidopa Unknown 25 mg

Indications